Expert Insights

PhUSE: Retrospective vs. Proactive Anonymization of Narratives

by PhUSE, March 14, 2019
This White Paper focuses on two approaches to produce anonymized narratives – retrospective and proactive. The retrospective section sheds light on the challenges faced with qualitative methods like redaction and what impact it has on data utility. The second part of this White Paper offers a perspective on proactive anonymization and how to operationalize it.

How #OneMMS Actively Supports Rare Disease Day

by Staff writer, February 28, 2018
Rare diseases are often overlooked, but they affect many individuals. There may be as many as 7,000 rare diseases affecting approximately 25-30 million people in the US alone, according to the National Institutes of Health (NIH). Rare diseases are defined as conditions that affect fewer than 200,000 people…

Writing for Regulatory Agencies vs. Medical Journals: The Differences

by Megan Day, AA, BA, PhD (ABD), January 17, 2019
Whether writing a clinical study report or a journal article, both illustrate the summarization of clinical trial data, serving multiple functions. Regardless of formatting, structure, and organizational limitations, medical writers are tasked with the ultimate goal of communicating complex data clearly and accurately.

How Real World Data is Changing the Pharmaceutical Industry

by Erin Booth, PhD, January 10, 2019
Approximately 90 percent of global pharmaceutical companies are using, or have plans to use real world data in the near future, according to a 2018 benchmarking survey from Deloitte. This coincides with an increased focus on the use of real world evidence from the U.S. Food & Drug Administration (FDA).

 

6880 Commerce Blvd.
Canton, MI 48187 USA
734.245.0310 T
734.245.0320 F

Email Us

FacebookLinkedIn

Learn more about working with MMS

8 + 14 =

© MMS Holdings Inc. All rights reserved. Privacy Policy